86 - Technology Transfer from Lab to Plant (S6E11)

Welcome to the deep dive. We're diving into a
crucial but often overlooked phase in the journey
of a new medicine, the leap from the lab to the
factory floor. This transition from a controlled
lab setting to large -scale commercial manufacturing
is packed with challenges, but it's absolutely
crucial to get it right. You hit the nail on
the head there. Think about it. How often do
we stop and think about the complexity behind
producing those everyday pills we rely on? Millions
of doses, all consistent and safe. That's quite
a feat. It truly is. Today we're pulling back
the curtain on this fascinating process known
as technology transfer. And to guide our exploration,
we'll be drawing insights from some real -world
case studies, especially from the journal Organic
Process Research and Development, or OPRND for
short. It's a treasure trove of practical examples
showcasing how scientists and engineers have
tackled these very challenges we're discussing.
OPRND is a great resource. So what's on the agenda
for our deep dive today? What are the key things
we want to uncover about this technology transfer?
Our mission today is pretty straightforward.
To shed light on the core elements of this transfer
process. We'll examine how knowledge is shared
between the research teams in the lab and the
people actually manufacturing the medicines on
the plant floor. We'll also unravel how quality
is maintained throughout this scaling up process
and discuss some of the unexpected hurdles that
pop up when you try to scale a lab process to
thousands of times its original size. And to
illustrate all of this, we'll be pulling in concrete
examples right from the pages of OPRND. Sounds
good. Let's start with the basics. You've developed
a great process in the lab. Let's say you're
making a few grams of a new drug. What's the
next step? How do you scale that up to produce
kilograms or even tons of the drug? It can't
be as simple as just using bigger equipment and
more ingredients, right? Absolutely not. Scaling
up is about navigating a whole new set of physical
realities. Imagine a lab flask. It's got a large
surface area relative to the volume of liquid
it holds. This makes temperature control pretty
straightforward. But now picture a massive reactor
in a manufacturing plant. The surface area to
volume ratio shrinks dramatically and suddenly
controlling the temperature evenly becomes a
major challenge. So the physics of the process
actually changes at a larger scale. Exactly.
This change in the physics can drastically alter
reaction rates and even lead to the formation
of byproducts you wouldn't see in the lab. I
see. What other fundamental factors change when
you scale up? Well, mass transfer is another
big one. It's all about how well your reactants
mix at the molecular level. Ensuring efficient
and consistent mixing in those huge industrial
vessels is a significant engineering challenge.
Because it's harder to stir things evenly in
a giant tank compared to a small flask. Precisely.
You can end up with the dead zones where mixing
is poor, leading to hot spots, or varying concentrations
of reactants. Remember those continuous flow
reactors we discussed from the OPR &D 2012 paper?
One of their main advantages over traditional
batch reactors is more efficient and predictable
mass transfer. The narrow channels in these reactors
ensure much better control over the reaction
compared to trying to stir a huge vat evenly.
Interesting. So the movement of molecules on
a tiny scale becomes a big engineering problem.
at a larger scale. And what about the chemistry
itself? Does the reaction proceed in the same
way when you scale up? While the basic chemical
transformation remains the same, the rate of
the reaction and the impurities that form can
be heavily influenced by those changes in physical
conditions we talked about, the temperature variations
and mixing efficiency. So even if the chemistry
is the same, the way it plays out can change
drastically. Exactly. For example, if you can't
remove heat effectively in a large reactor, you
might get localized overheating. This can accelerate
unwanted sig reactions and produce impurities
that were barely detectable in the lab. That's
why thorough process characterization is so important.
You need to understand how these scale -dependent
factors affect your reaction and design a process
that can handle those changes. So you've got
a promising lab process and you're starting to
figure out how it behaves at scale. What's the
next critical step in moving from the lab to
the production line? That's where knowledge transfer
comes in. The scientists who developed the process
in the lab need to train the manufacturing personnel
who'll be running it in the plant. This isn't
just about handing over a recipe, it's about
conveying all those subtle nuances and know -how.
It's like an apprenticeship for a very complex
chemical process. Exactly. While detailed documentation,
including standard operating procedures or SRPs,
is essential for regulatory compliance, like
those outlined in 21 CFR Part 211, it can't capture
everything. I can imagine. There's a lot of tacit
knowledge, things learned through experience,
that needs to be transferred through hands -on
training and close collaboration. A robust quality
system, guided by principles like ICHQ9 and good
drug regulatory practices, ensures that this
training is consistent and everyone follows procedures
rigorously. So skilled people following world
-defined steps are key to producing a consistent,
high -quality medicine. How do you then ensure
that the product coming out of the plant matches
the quality of what you are making in the lab?
That brings us to the crucial phase of quality
handover. This involves transferring analytical
methods and quality control procedures from the
development team to the quality control unit
in the manufacturing facility. These are the
tests that verify the identity, purity, potency,
and overall quality of the drug substance and
the final drug product in every single batch.
I see. So the scientists who develop the tests
need to teach the quality control team how to
run them and interpret the results. Absolutely.
And crucially, As mandated by regulations like
21 CFR Part 211, these analytical methods must
be verified under the actual conditions of the
plant's quality control labs. A test that works
perfectly in a research lab might not perform
the same way in a different environment. Different
instruments, different settings. It's important
to ensure the tests are reliable in their new
home. And what exactly are they checking for
during these quality control tests? They're mainly
focused on consistently meeting the critical
quality attributes or CQAs of the drug. These
are the properties that directly impact the safety
and effectiveness of the medicine. One interesting
challenge in maintaining these CQAs during scale
-up is the potential formation of different polymorphs.
Polymorphs, right. Different crystal structures
of the same molecule which can have different
properties. Precisely. As highlighted in sources
like OPRND 2012 D2 and the book Polymorphism
in the Pharmaceutical Industry, different polymorphs
can have very different characteristics like
solubility, stability, and even how they behave
during manufacturing. A new polymorph might emerge
during large -scale crystallization that wasn't
seen in the lab, and this could affect the drug's
performance. So thorough investigation and control
strategies to ensure you're producing the desired
crystal form consistently are crucial. A good
example of this is the study in OPR &D 2019b
where they compared batch and continuous flow
crystallization methods specifically for cGMP
manufacturing, emphasizing the focus on achieving
consistent solid form and product quality. So
even the way the drug molecules are arranged
in crystals needs to be controlled to avoid surprises.
Absolutely. Now let's delve into some specific
scaling challenges using real -world examples
from OPR &D to illustrate how complex this transition
can be. I'm all ears. Let's hear about some instances
where scale up didn't go as smoothly as planned.
One example is from OPR &D 2012. Researchers
were developing a more efficient process for
a key intermediate using continuous flow chemistry.
Their initial work with small -scale plug flow
reactors, or PFRs, was very promising. They successfully
scaled this up to a pilot plant, producing a
significant amount of material under GMP conditions.
This highlighted the potential of flow chemistry
for rapid development and scale up. However,
they didn't stop there. They developed a second
generation route that was even more efficient
and suitable for smaller scale commercial production.
So they kept refining the process for even better
scalability. What about an example where they
faced a more significant hurdle? The OPRND -2024
paper provides a good example. They were scaling
up a Grignard reaction using R -epichlorohydrin.
This reaction worked perfectly at a 1 gram scale
in the lab. However, when they tried it at a
25 gram scale, they saw a massive increase in
an unwanted side product. This forced them to
go back and meticulously re -optimize the reaction
conditions, like temperature and the rate of
reagent addition. It shows that a process that
seems perfect in the lab can behave very differently
at a larger scale. So you can't simply assume
that what works in the lab will translate directly
to manufacturing. Sometimes you need to re -optimize.
Exactly. And sometimes the impurities themselves
behave differently at scale. A good illustration
of this is the OPRND 2013 study on urea formation.
When they scaled up this reaction, they found
inconsistencies in the purification process due
to varying minor impurities. This sometimes resulted
in an unusable product. Their solution was to
introduce a silica gel plug filtration step,
which effectively removed these impurities. This
highlights how scaling up might require additional
purification steps that weren't needed in the
lab. It's fascinating how impurities can become
a bigger problem at larger scales. Do you have
another example of an unexpected scale up challenge?
Certainly. OPRND 2016C describes a case where
they had problems with emulsions forming during
the aqueous workup of a reaction at scale. In
the lab, separating the organic and water layers
after the reaction was easy. But at a larger
scale, they kept getting stubborn emulsions that
made it difficult to isolate the product. They
solved this by switching to a different solvent
system, a mixture of 2 -methyltetrahydrofuran,
or meth, and water. This change resulted in a
much cleaner and easier to scale process without
the emulsions. It shows how seemingly minor things
like solvent choice can significantly impact
scalability. These real -world examples really
highlight that technology transfer isn't always
straightforward. It often involves problem solving
and adapting to unexpected challenges. Absolutely.
And to tackle these challenges, the pharmaceutical
industry is increasingly using process analytical
technology, or PT. Hey, can you remind us what
that is? PT is basically about using sophisticated
sensors and analytical instruments directly within
the manufacturing equipment. As mentioned in
OPRND 2016c and OPRND 2021c, these tools can
continuously monitor things like temperature,
pressure, mixing, and even the composition of
the reaction mixture in real time. So instead
of taking samples and analyzing them separately,
you have constant feedback on what's happening
inside the reactor. Exactly. This allows for
much tighter control over the process and early
detection of deviations, minimizing the risk
of quality issues during scale -up and leading
to a more consistent product. Examples of these
PTAE tools include techniques like near -infrared
and Raman spectroscopy and ATR -FTIR, which is
particularly useful for controlling supersaturation
during crystallization. This deep dive has been
truly enlightening. It's amazing to see the complexity
involved in bringing a promising molecule from
the lab to a scale where it can benefit patients
worldwide. It really is. We've explored the importance
of understanding and addressing the changes that
come with scaling up, the significance of training
and quality handover, and the problem -solving
nature of technology transfer, all illustrated
by real -world experiences from OPR &D. This
often invisible stage is truly fundamental to
ensuring access to safe and effective medicines.
Absolutely. So the next time you take a medicine,
think about the incredible journey it has gone
through and the dedicated teams who made it possible.
It makes you appreciate the intricate processes
behind many everyday things we often take for
granted. It certainly does.